This kit is a molecular test for cervical carcinoma that is used in in vitro diagnosis. The test detects epigenetic changes characteristic for cancer cells with 6 biomarkers (ASTN1, DLX1, ITGA4, RXFP3, SOX17 and ZNF671) occurred specifically in cervical cancer or its precursors.
This non-invasive test, performed from just one cervical smear, examines the DNA of cells for changes that indicate cervical cancer and its preliminary stages, helping to clarify whether there is already a tissue alteration that needs to be treated. 
With its quick and reliable result, the kit can help prevent patients from this stressful period of uncertainty surrounding abnormal cervical cancer screening and follow-up results. Additionally, it can contribute to the optimization of resource distribution by avoiding excessive recourse to unnecessary diagonsis and treatment.

The kit qualitatively detects the methylation status of ASTN1, DLX1, ITGA4, RXFP3, SOX17 and ZNF671 genes in cervical scrapes,and confirms cervical cancer diagnosis with certainty for people with abnormal preliminary screening results, so as to achieve triage management.
When the test result is negative, it indicates that there is no cervical lesions or low-grade cervical lesions in patients. Unnecessary referral for colposcopy or tissue biopsy can be avoided. Instead, regular follow-up checks are recommended. If the test result is positive, it indicates that there is a high risk of cancer of the patients and further active diagnosis and/or treatments are required.

Package Size: 10 tests/kit

1. Sample Type: Cervical exfoliated cells.
2. Sample Collection: Scrape sample with a disposable cervical sampling swab, then immediately preserve it in cell preservation solution.
3. Storage Conditions: Room temperature: no more than 4 weeks; 2~8℃: no more than 12 weeks.

Storage Conditions: 2~8℃.
Validity Period: 12 months.